These tactics include expressing a series of receptors on the tumour cell surface, called immune checkpoints or immunosuppressive ligands; e.g., PD-L1, a transmembrane surface antigen with an immunoglobulin-like structure, is distributed in many tissues and interactions with PD-L1 lead to inhibition of T-cell receptor-mediated T-cell activation2. This evidence concerns the gene CD274 and neoplasm.